Whitehawk Therapeutics
WHWK
62 hedge funds and large institutions have $119M invested in Whitehawk Therapeutics in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 6 closing their positions.
250% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 6
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
51% more capital invested
Capital invested by funds: $79.2M → $119M (+$40.2M)
29% more funds holding
Funds holding: 48 → 62 (+14)
2.59% more ownership
Funds ownership: 69.97% → 72.57% (+2.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
87% less call options, than puts
Call options by funds: $9K | Put options by funds: $69K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.72M |
| 2 |
Millennium Management
New York
|
+$969K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$881K |
| 4 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$362K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$1.63M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$164K |
| 3 |
Two Sigma Investments
New York
|
-$114K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$75.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$57.6K |
WHWK Hedge Fund Activity: Q1 2026 in Review
62 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2026, worth a combined $119M — up 51% from $79.2M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new WHWK positions and 6 closed out — a net gain of 15 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.72M. The largest seller was Stempoint Capital, cutting an estimated $1.63M.
- 62 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2026, up from 48 in Q4 2025.
- Funds reported $119M of Whitehawk Therapeutics stock for Q1 2026, up 51% quarter-over-quarter.
- 21 funds opened new Whitehawk Therapeutics positions in Q1 2026 and 6 closed out, a net change of +15 holders.
- The largest Whitehawk Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $1.72M added.
- The largest Whitehawk Therapeutics seller in Q1 2026 was Stempoint Capital, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2026.